The novel autoantibody anti-p155 antibody (anti-TIF1-γ antibody) has recently emerged as a valuable diagnostic tool, whose presence is closely associated with cancer incidence in adult patients, with an estimated rate of 22%–100% of anti-TIF1-γ antibody-positive patients diagnosed with cancer (25). The gene discussed is TRIM33; the disease is cancer.